U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Go back to U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children| Pfizer Inc. (NYSE: PFE) | Delayed: 28.45 -0.36 (1.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.81 | 52 Week High | $37.39 | |||
| Open | $28.58 | 52 Week Low | $28.25 | |||
| Day High | $28.69 | P/E | 17.24 | |||
| Day Low | $28.38 | EPS | $1.65 | |||
| Volume | 23,791,983 | |||||
